Aquilus Pharmaceuticals Overview
- Year Founded
-
2009
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
4
Aquilus Pharmaceuticals General Information
Description
Operator of a biotech company intended for the treatment of neurodegenerative and nerve-related disorders. The company focuses on orally bioavailable enzyme inhibitors that modulate extracellular matrix degradation and inflammatory pathways, reduce nerve cell apoptosis, and target multiple molecular mechanisms implicated in neurological damage, enabling clients in the biotechnology and pharmaceutical research to advance preclinical and early-stage clinical development for conditions with unmet medical needs while providing a foundation for potential future therapeutic applications.
Contact Information
Website
www.aquiluspharma.comCorporate Office
- 225 Mystic Valley Parkway
- Winchester, MA 01890
- United States
Corporate Office
- 225 Mystic Valley Parkway
- Winchester, MA 01890
- United States
Aquilus Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Accelerator/Incubator | 02-Sep-2025 | Completed | Generating Revenue | |||
| 2. Accelerator/Incubator | 01-Jan-2024 | Completed | Generating Revenue | |||
| 1. Grant | 01-Jan-2011 | $3.56M | Completed | Generating Revenue |
Aquilus Pharmaceuticals Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Aquilus Pharmaceuticals Patents
Aquilus Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3130417-A1 | Compounds and methods for the treatment of degenerative disorders | Pending | 24-Jan-2019 | ||
| US-12589090-B2 | Compounds and methods for the treatment of degenerative disorders | Active | 24-Jan-2019 | ||
| US-20220047550-A1 | Compounds and methods for the treatment of degenerative disorders | Active | 24-Jan-2019 | ||
| WO-2020154243-A1 | Compounds and methods for the treatment of degenerative disorders | Inactive | 24-Jan-2019 | ||
| JP-2015166385-A | Compounds and methods for treatment of pain and other disorders | Pending | 29-May-2015 |
Aquilus Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Aquilus Pharmaceuticals Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| MassBio | Accelerator/Incubator | |||
| SCbio | Accelerator/Incubator | |||
| C2I Accelerator | Accelerator/Incubator | |||
| U.S. Department of Health and Human Services | Government |
Aquilus Pharmaceuticals FAQs
-
When was Aquilus Pharmaceuticals founded?
Aquilus Pharmaceuticals was founded in 2009.
-
Where is Aquilus Pharmaceuticals headquartered?
Aquilus Pharmaceuticals is headquartered in Winchester, MA.
-
What is the size of Aquilus Pharmaceuticals?
Aquilus Pharmaceuticals has 4 total employees.
-
What industry is Aquilus Pharmaceuticals in?
Aquilus Pharmaceuticals’s primary industry is Biotechnology.
-
Is Aquilus Pharmaceuticals a private or public company?
Aquilus Pharmaceuticals is a Private company.
-
What is Aquilus Pharmaceuticals’s current revenue?
The current revenue for Aquilus Pharmaceuticals is .
-
Who are Aquilus Pharmaceuticals’s investors?
MassBio, SCbio, C2I Accelerator, and U.S. Department of Health and Human Services have invested in Aquilus Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
